Lanreotide Depot/Autogel (Lan) In Pancreatic Neuroendocrine Tumors (Pnets): A Subgroup Analysis From The Clarinet Study.

Alexandria T. Phan,Martyn E. Caplin,Marianne E. Pavel,Jaroslaw B. Cwikla,Markus Raderer,Eva Sedlackova,Guillaume Cadiot,Edward M. Wolin,Jaume Capdevila,Lucy Wall,Guido Rindi,Alison Langley,Edda Gomez-Panzani,Philippe B. Ruszniewski

JOURNAL OF CLINICAL ONCOLOGY（2015）

引用 0|浏览22

暂无评分

摘要

233 Background: The prognosis for patients with metastatic pNETs is generally poor and current treatment options can be complicated by safety considerations. In CLARINET, progression-free survival (PFS) was significantly prolonged with the somatostatin analog LAN 120 mg vs. placebo (PBO) in patients with metastatic grade 1 or 2 (Ki-67 25...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要